Harvest One Cannabis Logo
Harvest One logo
toggle menu

Harvest One's CEO to Present at Biotech in Europe Forum

September 22, 2017

Harvest One Cannabis Inc. (TSXV:HVST) ("Harvest One" or the "Company") is pleased to advise that the Company’s CEO, Andreas Gedeon will be addressing the 17th Annual Biotech in Europe Forum which will be held on 26th-27th September 2017 at the Congress Center Basel in Switzerland.

Mr Gedeon has been invited to participate as a Speaker on the ‘Medical Cannabis and Opportunities in Europe’ panel, which will take place on Tuesday 26th September.

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. The event attracts a cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. The forum is recognised as a leading international platform for those interested in investing and partnering in the biotech and life science industry.

The panel will last approximately 45 minutes, and will include a brief presentation by each speaker, a roundtable discussion and audience Q&A.

About Harvest One Cannabis Inc. (TSX.V: HVST)

Harvest One controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation license, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.

For more information about Harvest One, please contact:

Colin Clancy
Communications
+ 1 (778) 855-2408
cclancy@mmj.ca

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Email Signup